Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Carboplatin plus mirvetuximab soravtansine followed by mirvetuximab continuation in FRα-positive platinum-sensitive recurrent ovarian cancer
2022-501220-14-00Phase 2Authorised
- Sponsor
- AbbVie Inc.
- Start
- Apr 2023
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 6
01
Overview
Phase 2, open-label, single-arm trial of mirvetuximab soravtansine and carboplatin in ovarian cancer, primary peritoneal cancer (PPC) and fallopian tube cancer (PFTC), sponsored by AbbVie Inc. Primary endpoint: Overall response rate in higher FRα expression subgroup. Planned start Apr 2023; status: authorised.
02
Drugs
mirvetuximab soravtansinecarboplatin
03
Conditions
ovarian cancerprimary peritoneal cancer (PPC)fallopian tube cancer (PFTC)
Beyond the preview
Go deeper on 2022-501220-14-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-501220-14-00.